

Vaccine Clinic Resource for Immunizers

Title:	COVID-19 Vaccine Quick Reference Guide
Formulations	mRNA (XBB.1.5 Variant), Recombinant protein- adjuvanted (XBB.1.5 Variant)
Effective Date:	Moderna Spikevax: September 12, 2023; Pfizer Comirnaty: September 28, 2023; Novavax Nuvaxovid: December 5, 2023
Approver:	Final

Disclaimer: *this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monographs and other resources online for all current and complete information.*

COVID-19 Vaccine Resources:

Product Monographs: [Province of Manitoba | Resources for Health Care Providers- product monographs \(gov.mb.ca\)](https://www.gov.mb.ca/health/immunization/product_monographs/)

Storage and Handling: [storage-handling-chart.pdf \(gov.mb.ca\)](https://www.gov.mb.ca/health/immunization/storage-handling-chart.pdf)

Eligibility Criteria

For the most up to date information on primary series and booster dose eligibility criteria refer to [Province of Manitoba | Eligibility Criteria \(gov.mb.ca\)](https://www.gov.mb.ca/health/immunization/eligibility_criteria/).

Canadian Immunization Guide:

For additional guidance on special populations: [COVID-19 vaccine: Canadian Immunization Guide- Vaccination of Specific Populations - Canada.ca](https://www.canada.ca/health/immunization/canadian-immunization-guide-vaccination-of-specific-populations/)

For information on allergies/contraindications/precautions: [COVID-19 vaccine: Canadian Immunization Guide -Contraindications and Precautions - Canada.ca](https://www.canada.ca/health/immunization/canadian-immunization-guide-contraindications-and-precautions/)

Fact Sheets:

For information on vaccine risk and intended benefits, refer to the [Province of Manitoba | Resources for the Public COVID-19 Fact Sheets \(gov.mb.ca\)](https://www.gov.mb.ca/health/immunization/fact-sheets/)

mRNA Vaccine	Pfizer/Comirnaty™ XBB.1.5 Variant Formulation: 6 months old to 4 years of age															
Presentation & Recommendations	Storage & Handling	Administration			Potential Allergens											
<p>Maroon cap Maroon label</p> <p>Supplied: 0.4 mL multi-dose vial</p> <p><u>Dilute with 2.2mL sterile 0.9% Sodium Chloride</u></p> <p>Number of doses per vial: 10 doses 3mcg/0.2mL after dilution</p> <p>Inspect vials: Prior to dilution, the thawed suspension may contain opaque amorphous particles. After dilution, the vaccine will be a white to off-white suspension. Do not administer if vaccine is discoloured or contains particulate matter.</p> <p><i>Low dead-volume syringes and/or needles can be used to extract 10 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract 10 doses from a single vial.</i></p>	<p>Thaw time: 2° to 8°C (Refrigerator): ➤ 2 hours <i>After thawing, let vial stand at room temperature for 15 minutes before dilution and administration.</i></p> <p>15° to 25° C (Room temperature): ➤ 30 min</p> <p>Storage: ➤ Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 10 weeks prior to first use. ➤ Unpunctured thawed vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours.</p> <p>Discard time: 12 hours at room or refrigerated temperature after first puncture. Do not refreeze.</p> <p>Handling: Before dilution, allow the thawed vial to come to room temperature. When at room temperature and between each withdrawal, mix by inverting vaccine vial gently 10 times. <u>Do not shake.</u></p>	<table border="1"> <thead> <tr> <th>Age Range</th> <th>COVID-19 Vaccination History</th> <th>Dose Timing</th> <th>Dose</th> <th>Dose Volume</th> </tr> </thead> <tbody> <tr> <td rowspan="2">6 months-4 years</td> <td>Previously vaccinated (primary series complete)</td> <td>One dose at least 3 months* after previous COVID-19 vaccine dose or known infection</td> <td rowspan="2">3mcg</td> <td rowspan="2">0.2mL</td> </tr> <tr> <td>Not previously vaccinated</td> <td>3-dose series: minimum 3 weeks between dose #1 and #2. Minimum 8 weeks between dose #2 and #3 <i>(Note: If recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 weeks.)</i></td> </tr> </tbody> </table>	Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume	6 months-4 years	Previously vaccinated (primary series complete)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	3mcg	0.2mL	Not previously vaccinated	3-dose series: minimum 3 weeks between dose #1 and #2. Minimum 8 weeks between dose #2 and #3 <i>(Note: If recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 weeks.)</i>	<p><i>*The recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection.</i></p> <p>Infants or children who have received a dose of Pfizer/Comirnaty™ XBB.1.5 should receive Pfizer/Comirnaty™ XBB.1.5 to complete the three-dose course if possible. If not possible, the dose recommendations should be as follows:</p> <ul style="list-style-type: none"> • 2 doses of Pfizer + 1 dose of Moderna • 1 dose of Pfizer + 2 doses of Moderna <p>Route: Intramuscular (IM) ➤ 6m to less than 12m of age: IM Anterolateral thigh ➤ 12m and older: IM Deltoid</p> <p>Recommended needle gauge and length: 22-25G 1"-1 ½ " <i>Clinical judgement should be used when selecting needle length for IM injections. Consider client's weight, age, and muscle mass.</i></p>	<p>Product is latex and preservative free.</p> <p>Potential allergens: ➤ Polyethylene glycol (PEG), ➤ Tromethamine (trometamol or Tris)</p> <p><i>Individuals who have a known allergy to Tromethamine (trometamol or Tris), should not be immunized with COVID-19 vaccines containing Tromethamine (trometamol or Tris).</i></p> <p><i>Individuals who report an allergy to contrast material (CT dye), including gadolinium, can be immunized with vaccines containing Tromethamine (trometamol or Tris). They should be observed for 30 minutes post immunization.</i></p>
Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume												
6 months-4 years	Previously vaccinated (primary series complete)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	3mcg	0.2mL												
	Not previously vaccinated	3-dose series: minimum 3 weeks between dose #1 and #2. Minimum 8 weeks between dose #2 and #3 <i>(Note: If recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 weeks.)</i>														

mRNA Vaccine	Pfizer/Comirnaty™ XBB.1.5 Variant Formulation: 5 years to 11 years of age																
Presentation & Recommendations	Storage & Handling	Administration			Potential Allergens												
<p>Blue cap Blue label</p> <p>Supplied: 2.25 mL multi-dose vial</p> <p>Does NOT require dilution.</p> <p>Number of doses per vial: 6 doses 10mcg/0.3mL</p> <p>Inspect vials: The thawed suspension may contain white to off-white opaque amorphous particles. Do not administer if vaccine is discoloured or contains particulate matter.</p> <p><i>Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract a 6th dose from a single vial.</i></p>	<p>Thaw time: <u>2° to 8°C (Refrigerator):</u> ➤ 6 hours <i>After thawing, let vial stand at room temperature for 15 minutes before administering.</i> <u>15° to 25° C (Room temperature):</u> ➤ 30 min</p> <p>Storage: ➤ Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 10 weeks prior to first use. ➤ Unpunctured thawed vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours.</p> <p>Discard time: 12 hours at room or refrigerated temperature after first puncture. Do not refreeze.</p> <p>Handling: Allow the thawed vial to come to room temperature. When at room temperature and between each withdrawal, mix by inverting vaccine vial gently 10 times. <u>Do not shake.</u></p>	<table border="1"> <thead> <tr> <th>Age Range</th> <th>COVID-19 Vaccination History</th> <th>Dose Timing</th> <th>Dose</th> <th>Dose Volume</th> </tr> </thead> <tbody> <tr> <td rowspan="2">5-11 years</td> <td>Previously vaccinated (primary series complete)</td> <td>One dose at least 3 months* after previous COVID-19 vaccine dose or known infection</td> <td rowspan="2">10mcg</td> <td rowspan="2">0.3mL</td> </tr> <tr> <td>Not previously vaccinated (or primary series not complete)</td> <td>One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection</td> </tr> </tbody> </table> <p><i>*The recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection.</i></p> <p>Route: Intramuscular (IM) Deltoid Recommended needle gauge and length: 22-25G 1"-1 ½ " <i>Clinical judgement should be used when selecting needle length for IM injections. Consider client's weight, age, and muscle mass.</i></p>			Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume	5-11 years	Previously vaccinated (primary series complete)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	10mcg	0.3mL	Not previously vaccinated (or primary series not complete)	One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection	<p>Product is latex and preservative free.</p> <p>Potential allergens: ➤ Polyethylene glycol (PEG), ➤ Tromethamine (trometamol or Tris)</p> <p><i>Individuals who have a known allergy to Tromethamine (trometamol or Tris), should not be immunized with COVID-19 vaccines containing Tromethamine (trometamol or Tris).</i></p> <p><i>Individuals who report an allergy to contrast material (CT dye), including gadolinium, can be immunized with vaccines containing Tromethamine (trometamol or Tris). They should be observed for 30 minutes post immunization.</i></p>
Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume													
5-11 years	Previously vaccinated (primary series complete)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	10mcg	0.3mL													
	Not previously vaccinated (or primary series not complete)	One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection															

mRNA Vaccine	Pfizer/Comirnaty™ XBB.1.5 Variant Formulation: 12 years of age and older																		
Presentation & Recommendations	Storage & Handling	Administration				Potential Allergens													
<p>Gray cap Gray label</p> <p>Supplied: 2.25 mL multidose vial</p> <p>Does NOT require dilution.</p> <p>Number of doses per vial: 6 doses per vial 30 mcg/0.3mL</p> <p>Inspect vials: The thawed suspension may contain white to off-white opaque amorphous particles. Do not administer if vaccine is discoloured or contains particulate matter.</p> <p><i>Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract a 6th dose from a single vial.</i></p>	<p>Thaw time: <u>2° to 8°C (Refrigerator):</u> ➤ 6 hours <i>After thawing, let vial stand at room temperature for 15 minutes before administering.</i> <u>15° to 25° C (Room temperature):</u> ➤ 30 min</p> <p>Storage: ➤ Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 10 weeks prior to first use. ➤ Unpunctured thawed vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours prior to use.</p> <p>Discard time: 12 hours at room or refrigerated temperature after first puncture. Do not refreeze.</p> <p>Handling: Allow the thawed vial to come to room temperature. When at room temperature and between each withdrawal, mix by inverting vaccine vial gently 10 times. Do not shake.</p>	<table border="1"> <thead> <tr> <th>Age Range</th> <th>COVID-19 Vaccination History</th> <th>Dose Timing</th> <th>Dose</th> <th>Dose Volume</th> </tr> </thead> <tbody> <tr> <td rowspan="2">12 years and older</td> <td>Previously vaccinated (primary series complete)</td> <td>One dose at least 3 months* after previous COVID-19 vaccine dose or known infection</td> <td rowspan="2">30mcg</td> <td rowspan="2">0.3mL</td> </tr> <tr> <td>Not previously vaccinated (or primary series not complete)</td> <td>One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection</td> </tr> </tbody> </table>					Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume	12 years and older	Previously vaccinated (primary series complete)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	30mcg	0.3mL	Not previously vaccinated (or primary series not complete)	One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection	<p>Product is latex and preservative free.</p> <p>Potential allergens: ➤ Polyethylene glycol (PEG), ➤ Tromethamine (trometamol or Tris)</p> <p><i>Individuals who have a known allergy to Tromethamine (trometamol or Tris), should not be immunized with COVID-19 vaccines containing Tromethamine (trometamol or Tris).</i></p> <p><i>Individuals who report an allergy to contrast material (CT dye), including gadolinium, can be immunized with vaccines containing Tromethamine (trometamol or Tris). They should be observed for 30 minutes post immunization.</i></p>
		Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume													
12 years and older	Previously vaccinated (primary series complete)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	30mcg	0.3mL															
	Not previously vaccinated (or primary series not complete)	One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection																	
<p><i>*The recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection.</i></p> <p>The following are eligible for another dose of XBB.1.5 COVID-19 vaccine if it has been at least 3 months from their most recent COVID-19 vaccine dose:</p> <ul style="list-style-type: none"> • Adults 65 years of age and older • Indigenous people 45 years of age and older, including First Nations, Inuit and Metis peoples, regardless of place of residence • Adult residents of long-term care homes and other congregate living settings for seniors <p>Route: Intramuscular (IM) Deltoid Recommended needle gauge and length: 22-25G 1"-1 ½ " <i>Clinical judgement should be used when selecting needle length for IM injections. Consider client's weight, age, and muscle mass.</i></p>																			

mRNA Vaccine		Moderna SPIKEVAX™ XBB.1.5 Variant Formulation: 6 months of age and older					
Presentation & Recommendations	Storage & Handling	Administration				Potential Allergens	
		Age Range	COVID-19 Vaccination History	Dose Timing	Dose		Dose Volume
<p>Royal Blue cap Coral Blue label</p> <p>Supplied: 2.5 ml multidose vial Concentration: 0.10 mg/ml</p> <p>Does NOT require dilution.</p> <p>Number of doses per vial: 10 doses of 0.25ml per vial OR 5 doses of 0.5ml per vial</p> <p>Inspect vials: White/off-white dispersion and may contain white or translucent product-related particulates.</p> <p>If solution contains foreign particulates or discoloration, do not administer.</p>	<p>Thaw time: <u>2° to 8°C (Refrigerator):</u> ➤ 2 hours <i>After thawing, let vial stand at room temperature for 15 minutes before administering.</i> <u>15° to 25° C (Room temperature):</u> ➤ 45 min</p> <p>Storage: ➤ Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use. ➤ Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 24 hours.</p> <p>Discard time: 24 hours at room or refrigerated temperature after first puncture. Do not refreeze.</p> <p>Handling: Swirl the vial gently after thawing and between each withdrawal. <u>Do not shake.</u></p>	<p>6 months-4 years ⚠</p> <p>Previously vaccinated (primary series complete) ➤ One dose at least 3 months* after previous COVID-19 vaccine dose or known COVID infection</p> <p>Not previously vaccinated (or primary series not complete) ➤ 2-dose series at least 4 weeks apart <i>(Note: If not previously vaccinated and recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 weeks.)</i></p>	<p>5-11 years</p> <p>Previously vaccinated (primary series complete) ➤ One dose at least 3 months* after previous COVID-19 vaccine dose or known COVID infection</p> <p>Not previously vaccinated (or primary series not complete) ➤ One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection</p>	<p>12 years and older</p> <p>Previously vaccinated (primary series complete) ➤ One dose at least 3 months* after previous COVID-19 vaccine dose or known COVID infection</p> <p>Not previously vaccinated (or primary series not complete) ➤ One dose at least 4 weeks after previous COVID-19 vaccine dose or known infection</p>	<p>25mcg</p> <p>2x25mcg</p> <p>25mcg</p> <p>50mcg</p>	<p>0.25ml</p> <p>0.25ml</p> <p>0.5ml</p>	<p>Product is latex and preservative free.</p> <p>Potential allergens: ➤ Polyethylene glycol (PEG), ➤ Tromethamine (trometamol or Tris)</p> <p><i>Individuals who have a known allergy to Tromethamine (trometamol or Tris), should not be immunized with COVID-19 vaccines containing Tromethamine (trometamol or Tris).</i></p> <p><i>Individuals who report an allergy to contrast material (CT dye), including gadolinium, can be immunized with vaccines containing Tromethamine (trometamol or Tris). They should be observed for 30 minutes post immunization.</i></p>
		<p>*The recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection</p> <p>⚠If the primary series was started with Pfizer and will be completed with Moderna, the dose schedule is as follows:</p> <ul style="list-style-type: none"> • 2 doses of Pfizer + 1 dose of Moderna • 1 dose of Pfizer + 2 doses of Moderna <p>The following are eligible for another dose of XBB.1.5 COVID-19 vaccine if it has been at least 3 months from their most recent COVID-19 vaccine dose:</p> <ul style="list-style-type: none"> • Adults 65 years of age and older • Indigenous people 45 years of age and older, including First Nations, Inuit and Metis peoples, regardless of place of residence • Adult residents of long-term care homes and other congregate living settings for seniors <p>Route: Intramuscular (IM) ➤ 6m to less than 12m of age: IM Anterolateral thigh ➤ 12m and older: IM Deltoid</p> <p>Recommended needle gauge and length: 22-25G 1"-1 ½ "</p> <p><i>Clinical judgement should be used when selecting needle length for IM injections. Consider client's weight, age, and muscle mass.</i></p>					

Recombinant Protein, Adjuvanted	Novavax NUVAXOVID™ XBB.1.5 Variant Formulation: 12 years of age and older																
Presentation & Recommendations	Storage & Handling	Administration			Potential Allergens												
<p>Blue cap White label</p> <p>Supplied: 2.5 mL multidose vial</p> <p>Does NOT require dilution.</p> <p>Number of doses per vial: 5 doses of 0.5ml per vial</p> <p>Inspect vials: Colorless to slightly yellow, clear to mildly opalescent suspension, free of particles.</p> <p>If solution contains foreign particulates or discoloration, do not administer.</p>	<p>Storage:</p> <ul style="list-style-type: none"> Unpunctured vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 12 months prior to first use (protect from light). Do not use this vaccine after the expiry date, which is stated on the label and refers to the last day of that month. <p>Discard time: 12 hours at refrigerated temperature or 6 hours at room temperature after first puncture. Do not freeze.</p> <p>Handling: Gently swirl the multidose vial before and in between each dose withdrawal. Do not shake. Do not shake.</p>	<table border="1"> <thead> <tr> <th data-bbox="903 402 1150 516">Age Range</th> <th data-bbox="1161 402 1408 516">COVID-19 Vaccination History</th> <th data-bbox="1419 402 1650 516">Dose Timing</th> <th data-bbox="1661 402 1892 516">Dose</th> <th data-bbox="1903 402 2134 516">Dose Volume</th> </tr> </thead> <tbody> <tr> <td data-bbox="903 522 1150 1029" rowspan="2">12 years and older</td> <td data-bbox="1161 522 1408 756">Previously vaccinated with 1 or more dose(s)</td> <td data-bbox="1419 522 1650 756">One dose at least 3 months* after previous COVID-19 vaccine dose or known infection</td> <td data-bbox="1661 522 1892 1029" rowspan="2">5 mcg</td> <td data-bbox="1903 522 2134 1029" rowspan="2">0.5ml</td> </tr> <tr> <td data-bbox="1161 763 1408 1029">Not previously vaccinated</td> <td data-bbox="1419 763 1650 1029">Two doses 3 weeks apart (Note: If recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 weeks.)</td> </tr> </tbody> </table> <p><i>*The recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection.</i></p> <p>The following are eligible for another dose of XBB.1.5 COVID-19 vaccine if it has been at least 3 months from their most recent COVID-19 vaccine dose:</p> <ul style="list-style-type: none"> adults 65 years of age and older, indigenous people 45 years of age and older, including First Nations, Inuit, and Metis peoples, regardless of place of residence, adult residents of long-term care homes and other congregate living settings for seniors. <p>Route: Intramuscular (IM) Deltoid Recommended needle gauge and length: 22-25G 1"-1 ½ " <i>Clinical judgement should be used when selecting needle length for IM injections. Consider client's weight, age, and muscle mass.</i></p>			Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume	12 years and older	Previously vaccinated with 1 or more dose(s)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	5 mcg	0.5ml	Not previously vaccinated	Two doses 3 weeks apart (Note: If recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 weeks.)	<p>Product is latex and preservative free.</p> <p>Potential allergens (non-medicinal ingredients):</p> <ul style="list-style-type: none"> Disodium hydrogen phosphate heptahydrate Hydrochloric acid (for adjustment of pH) Polysorbate 80 Sodium chloride Sodium dihydrogen phosphate monohydrate Sodium hydroxide (for adjustment of pH) <p><i>For adjuvant:</i></p> <ul style="list-style-type: none"> Cholesterol Disodium hydrogen phosphate dihydrate Phosphatidylcholine Potassium chloride Potassium dihydrogen phosphate Sodium chloride
Age Range	COVID-19 Vaccination History	Dose Timing	Dose	Dose Volume													
12 years and older	Previously vaccinated with 1 or more dose(s)	One dose at least 3 months* after previous COVID-19 vaccine dose or known infection	5 mcg	0.5ml													
	Not previously vaccinated	Two doses 3 weeks apart (Note: If recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 weeks.)															

Additional Dose Recommendations: Moderately to Severely Immunocompromised^{1,2} (COVID-19 mRNA vaccines are the preferentially recommended COVID-19 vaccines)

If not previously immunized or if partially immunized against COVID-19:

Cohort	Product	Dose	Recommended Interval
6 months to 4 years	Moderna/ Spikevax™ XBB.1.5 (0.25 mL – 25 mcg) Blue cap/ Coral Blue label <i>(Preferential vaccine for this age group due to the shorter 3 dose regimen)</i>	3 dose series	<p><i>If recently infected with COVID-19, it is recommended to delay the next COVID-19 vaccine dose by 4 to 8 weeks. Your health care provider may recommend a different immunization schedule for you based on a review of your medical history and individual circumstances. A prescription is required for the additional doses.</i></p>
	Pfizer/Comirnaty™ XBB.1.5 (0.2mL – 3 mcg) Maroon cap/ Maroon label <i>Children who have received a dose of Pfizer/Comirnaty™ XBB.1.5 should receive Pfizer/Comirnaty™ XBB.1.5 to complete the series if possible.</i>	4 dose series	
5 to 11 years	Moderna/ Spikevax™ XBB.1.5 (0.25 mL – 25 mcg) Blue cap/ Coral Blue label	3 dose series	
	Pfizer/Comirnaty™ XBB.1.5 (0.3mL – 10 mcg) Blue cap/ Blue label		
12 years and older	Moderna/Spikevax™ XBB.1.5 (0.5mL – 50 mcg) Blue cap/ Coral Blue label		
	Pfizer/Comirnaty™ XBB.1.5 (0.3mL – 30 mcg) Gray cap/ Gray label		
	Novavax/ Nuvaxovid™ XBB.1.5 (0.5ml – 5 mcg) Blue cap/ white label	3 dose series	

If having previously completed a COVID-19 vaccine primary series:

In addition to the fall 2023 dose, individuals 6 months of age and older who are moderately to severely immunocompromised are eligible for **another dose of XBB.1.5 COVID-19 vaccine**, provided it has been at least 3 months from their most recent COVID-19 vaccine dose. The recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection.

¹For the purposes of COVID-19 vaccine recommendations, the following individuals are considered moderately to severely immunocompromised due to a medical condition and/or treatment:

- are receiving active chemotherapy (or immunotherapy) for cancer,
- have received a solid organ transplant and are currently receiving chemotherapy or other immunosuppressive therapy,
- were born with moderate or severe dysfunction of their immune system,
- are living with untreated or advanced HIV-AIDS or
- are taking certain medications that severely affect the immune system.

²The following people should talk to their doctor to see if they are considered immunocompromised:

- receiving hemodialysis or peritoneal dialysis,
- are on the list to receive a solid organ transplant or
- have a ventricular assist device (VAD)